Biome Australia (ASX: BIO) has drawn attention as one of the few small-cap healthcare companies combining strong revenue growth with genuine profitability. After reporting record full-year revenue and a record half-year EBITDA, the microbiome-focused company is demonstrating that its probiotics business is scaling while staying in the black — a rare profile among emerging ASX health stocks and one that has put its shares back on investors’ radars.

Company and technology overview

Biome Australia is a health company specialising in live microbiome and probiotic products — formulations containing beneficial bacteria intended to support digestive, immune and general health. Its flagship Activated Probiotics range is sold primarily through Australian community pharmacies and, increasingly, internationally. The company differentiates its products with evidence-based, condition-specific formulations, positioning them toward the practitioner and pharmacy channel rather than commodity supplements. Biome has described Activated Probiotics as the number-one probiotic brand by revenue in Australian community pharmacy, with Biome Daily among its leading individual products.

The latest development

Biome reported record FY26 sales revenue of approximately A$23.9 million, up around 30% on the prior year. The strength was underpinned by its first-half FY26 result (for the six months ended 31 December 2025), which delivered revenue of about A$12.4 million, up roughly 40% on the prior corresponding period, and record half-year EBITDA (earnings before interest, tax, depreciation and amortisation) of A$1.47 million excluding share-based payments. Net profit for the half rose 172% to A$1.18 million, and the company noted its eighth consecutive quarter of positive EBITDA. Same-store sales in Australia grew about 39%, and international revenue rose about 26% to A$1.8 million. Biome also signed a manufacturing agreement in June 2026, targeting its first commercial batch around September 2026.

Financial evidence and what it means

Biome’s results stand out because they show profitable growth rather than growth funded by losses. A first-half gross margin of about 61% (broadly stable year on year) reflects the premium positioning of its products, and the run of positive EBITDA quarters indicates operating discipline as the business scales. Reaching a first net profit in FY25 and then growing it sharply in the first half of FY26 suggests the model is producing operating leverage — revenue growing faster than costs. The move to secure its own manufacturing arrangement could, over time, support margins and supply reliability. These are encouraging signs, though EBITDA excludes some real costs, so net profit and cash flow remain the more complete measures of financial health.

Biome shares have recovered and re-rated as investors weighed its FY26 growth momentum, and earlier updates on record revenue were reported to have driven notable share-price gains. As a small-cap, the stock can still be volatile around results. Readers should confirm the current share price and any recent movement against a live market source, noting the date and timeframe, rather than relying on a single figure.

Funding position and cash runway

Unlike many small-cap health companies that burn cash, Biome is generating positive EBITDA and net profit, which reduces its dependence on external funding. The company reported cash of about A$3.36 million at 31 December 2025 and had reduced borrowings, a healthier balance-sheet trajectory. Because the business is profitable and cash-generative at the operating level, the traditional "cash runway" framing is less pressing than for pre-revenue peers; nonetheless, investors should confirm the latest cash position and working-capital needs against Biome’s most recent financial report, particularly as it funds inventory and its new manufacturing arrangement.

Commercial opportunity and addressable market

The global market for probiotics and microbiome products is large and growing, driven by rising consumer interest in gut health and preventive wellness. Biome’s strategy of evidence-based, pharmacy-channel products targets a premium segment less exposed to commodity price competition. Its leadership position in Australian community pharmacy provides a base for further domestic penetration, while international expansion — still small at about A$1.8 million in revenue — represents a longer-term growth avenue. Capturing that opportunity depends on continued brand strength, new product development and successful expansion beyond its home market.

Upcoming catalysts

Key catalysts include full-year FY26 profit and cash-flow confirmation, continued growth in both domestic same-store sales and international revenue, the successful commissioning of its new manufacturing arrangement from around September 2026, and any new product launches or channel expansion. Sustained positive EBITDA and margin trends will be closely watched. Management’s growth commentary is forward-looking and should be treated as expectation rather than certainty.

Principal risks and uncertainties

Risks include the possibility that growth slows as the business matures, competition intensifies in the probiotics category, or margins come under pressure from input costs or channel dynamics. Execution risk attaches to the new manufacturing arrangement and to international expansion. As a small-cap, Biome’s shares can be volatile, and its valuation may already reflect a good deal of optimism, leaving less room for disappointment. Regulatory and quality requirements for live-bacteria products are also demanding.

Conclusion

Is Biome becoming a profitable growth story? On the evidence of its FY26 results, it already is one: record revenue, record half-year EBITDA, a rising net profit and an unbroken run of positive quarterly earnings distinguish it from the many loss-making small-caps in the sector. The measured caveats are scale and expectations — Biome is still a modest business, and much of its future international growth remains to be proven. But the combination of growth and profitability is real and unusual, making Biome one of the more financially grounded stories among emerging ASX health companies.